United States Neurotherapeutic Drugs Market Report 2017

December 2017 | 101 pages | ID: U5F3B2D62DDEN
QYResearch

Abstracts

In this report, the United States Neurotherapeutic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Neurotherapeutic Drugs in these regions, from 2012 to 2022 (forecast).

United States Neurotherapeutic Drugs market competition by top manufacturers/players, with Neurotherapeutic Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Abbott
• BD
• Novartis AG
• Johnson & Johnson
• Pfizer
• Sanofi-Aventis
• Biogen
• GlaxoSmithKline
• AstraZeneca
• Merck

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Peripheral Nervous System Disorders (PNS) Disorder
• Autonomous Nervous System (ANS) Disorder
• Central Nervous System (CNS) Disorders
• Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hosptical
• Drug Stores
• Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Neurotherapeutic Drugs Market Report 2017

1 NEUROTHERAPEUTIC DRUGS OVERVIEW

1.1 Product Overview and Scope of Neurotherapeutic Drugs
1.2 Classification of Neurotherapeutic Drugs by Product Category
  1.2.1 United States Neurotherapeutic Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Neurotherapeutic Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Peripheral Nervous System Disorders (PNS) Disorder
  1.2.4 Autonomous Nervous System (ANS) Disorder
  1.2.5 Central Nervous System (CNS) Disorders
  1.2.6 Other
1.3 United States Neurotherapeutic Drugs Market by Application/End Users
  1.3.1 United States Neurotherapeutic Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hosptical
  1.3.3 Drug Stores
  1.3.4 Other
1.4 United States Neurotherapeutic Drugs Market by Region
  1.4.1 United States Neurotherapeutic Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Neurotherapeutic Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Neurotherapeutic Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Neurotherapeutic Drugs Status and Prospect (2012-2022)
  1.4.5 New England Neurotherapeutic Drugs Status and Prospect (2012-2022)
  1.4.6 The South Neurotherapeutic Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Neurotherapeutic Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Neurotherapeutic Drugs (2012-2022)
  1.5.1 United States Neurotherapeutic Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Neurotherapeutic Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES NEUROTHERAPEUTIC DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Neurotherapeutic Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Neurotherapeutic Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Neurotherapeutic Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Neurotherapeutic Drugs Market Competitive Situation and Trends
  2.4.1 United States Neurotherapeutic Drugs Market Concentration Rate
  2.4.2 United States Neurotherapeutic Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Neurotherapeutic Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES NEUROTHERAPEUTIC DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Neurotherapeutic Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Neurotherapeutic Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Neurotherapeutic Drugs Price by Region (2012-2017)

4 UNITED STATES NEUROTHERAPEUTIC DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Neurotherapeutic Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Neurotherapeutic Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Neurotherapeutic Drugs Price by Type (2012-2017)
4.4 United States Neurotherapeutic Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES NEUROTHERAPEUTIC DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Neurotherapeutic Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Neurotherapeutic Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES NEUROTHERAPEUTIC DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Abbott
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Abbott Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 BD
  6.2.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 BD Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Novartis AG
  6.3.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Novartis AG Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Johnson & Johnson
  6.4.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Johnson & Johnson Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer
  6.5.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Sanofi-Aventis
  6.6.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Sanofi-Aventis Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Biogen
  6.7.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Biogen Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 GlaxoSmithKline
  6.8.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 GlaxoSmithKline Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 AstraZeneca
  6.9.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 AstraZeneca Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Merck
  6.10.2 Neurotherapeutic Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Merck Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 NEUROTHERAPEUTIC DRUGS MANUFACTURING COST ANALYSIS

7.1 Neurotherapeutic Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Neurotherapeutic Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Neurotherapeutic Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Neurotherapeutic Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES NEUROTHERAPEUTIC DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Neurotherapeutic Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Neurotherapeutic Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Neurotherapeutic Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Neurotherapeutic Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Neurotherapeutic Drugs
Figure United States Neurotherapeutic Drugs Market Size (K Units) by Type (2012-2022)
Figure United States Neurotherapeutic Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Peripheral Nervous System Disorders (PNS) Disorder Product Picture
Figure Autonomous Nervous System (ANS) Disorder Product Picture
Figure Central Nervous System (CNS) Disorders Product Picture
Figure Other Product Picture
Figure United States Neurotherapeutic Drugs Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Neurotherapeutic Drugs by Application in 2016
Figure Hosptical Examples
Table Key Downstream Customer in Hosptical
Figure Drug Stores Examples
Table Key Downstream Customer in Drug Stores
Figure Other Examples
Table Key Downstream Customer in Other
Figure United States Neurotherapeutic Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Neurotherapeutic Drugs Sales (K Units) and Growth Rate (2012-2022)
Figure United States Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Neurotherapeutic Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Neurotherapeutic Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Neurotherapeutic Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Neurotherapeutic Drugs Sales Share by Players/Suppliers
Figure 2017 United States Neurotherapeutic Drugs Sales Share by Players/Suppliers
Figure United States Neurotherapeutic Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Neurotherapeutic Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Neurotherapeutic Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Neurotherapeutic Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Neurotherapeutic Drugs Revenue Share by Players/Suppliers
Table United States Market Neurotherapeutic Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Neurotherapeutic Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Neurotherapeutic Drugs Market Share of Top 3 Players/Suppliers
Figure United States Neurotherapeutic Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Neurotherapeutic Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Neurotherapeutic Drugs Product Category
Table United States Neurotherapeutic Drugs Sales (K Units) by Region (2012-2017)
Table United States Neurotherapeutic Drugs Sales Share by Region (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Share by Region (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Market Share by Region in 2016
Table United States Neurotherapeutic Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Neurotherapeutic Drugs Revenue Share by Region (2012-2017)
Figure United States Neurotherapeutic Drugs Revenue Market Share by Region (2012-2017)
Figure United States Neurotherapeutic Drugs Revenue Market Share by Region in 2016
Table United States Neurotherapeutic Drugs Price (USD/Unit) by Region (2012-2017)
Table United States Neurotherapeutic Drugs Sales (K Units) by Type (2012-2017)
Table United States Neurotherapeutic Drugs Sales Share by Type (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Share by Type (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Market Share by Type in 2016
Table United States Neurotherapeutic Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Neurotherapeutic Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Neurotherapeutic Drugs by Type (2012-2017)
Figure Revenue Market Share of Neurotherapeutic Drugs by Type in 2016
Table United States Neurotherapeutic Drugs Price (USD/Unit) by Types (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Growth Rate by Type (2012-2017)
Table United States Neurotherapeutic Drugs Sales (K Units) by Application (2012-2017)
Table United States Neurotherapeutic Drugs Sales Market Share by Application (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Market Share by Application (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Market Share by Application in 2016
Table United States Neurotherapeutic Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Neurotherapeutic Drugs Sales Growth Rate by Application (2012-2017)
Table Abbott Basic Information List
Table Abbott Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Abbott Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure Abbott Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure Abbott Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table BD Basic Information List
Table BD Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure BD Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure BD Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure BD Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis AG Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure Novartis AG Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure Novartis AG Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Johnson & Johnson Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure Pfizer Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure Pfizer Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table Sanofi-Aventis Basic Information List
Table Sanofi-Aventis Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi-Aventis Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure Sanofi-Aventis Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure Sanofi-Aventis Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table Biogen Basic Information List
Table Biogen Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Biogen Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure Biogen Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure Biogen Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AstraZeneca Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure AstraZeneca Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure AstraZeneca Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Neurotherapeutic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck Neurotherapeutic Drugs Sales Growth Rate (2012-2017)
Figure Merck Neurotherapeutic Drugs Sales Market Share in United States (2012-2017)
Figure Merck Neurotherapeutic Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Neurotherapeutic Drugs
Figure Manufacturing Process Analysis of Neurotherapeutic Drugs
Figure Neurotherapeutic Drugs Industrial Chain Analysis
Table Raw Materials Sources of Neurotherapeutic Drugs Major Players/Suppliers in 2016
Table Major Buyers of Neurotherapeutic Drugs
Table Distributors/Traders List
Figure United States Neurotherapeutic Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Neurotherapeutic Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Neurotherapeutic Drugs Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Neurotherapeutic Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Neurotherapeutic Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Neurotherapeutic Drugs Sales Volume (K Units) Forecast by Type in 2022
Table United States Neurotherapeutic Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Neurotherapeutic Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Neurotherapeutic Drugs Sales Volume (K Units) Forecast by Application in 2022
Table United States Neurotherapeutic Drugs Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Neurotherapeutic Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Neurotherapeutic Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Neurotherapeutic Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources